Protalix is a publicly traded biotechnology company
(NYSE Amex: PLX),
that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.
ABOUT US
Corporate Profile
Market Needs
Protalix Advantage
Management Team
Scientific Advisory Board
Press Room
Careers
TECHNOLOGY
ProCellEx Overview
Platform Technology
Protein Production
PRODUCT DEVELOPMENT
taliglucerase alfa (UPLYSO)
Pipeline Products
PARTNERSHIPS
INVESTORS
Corporate Strategy
Board of Directors
Management Team
Stock Information
Corporate Governance
Filings
Analyst Coverage
Press Releases
FAQs
PATIENTS
EVENT CALENDER
OPEN POSITIONS
CONTACT US
Patients
Investor Relations
PRESS ROOM
03/10/10
Protalix [PLX] Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors
03/03/10
Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
02/11/10
Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium
02/04/10
Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network
02/02/10
Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease
01/13/10
European Medicines Agency′s COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix′s taliglucerase alfa
12/09/09
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher′s Disease
12/01/09
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
10/29/09
Protalix BioTherapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference
10/15/09
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease
09/22/09
Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
09/14/09
Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease
09/08/09
FDA Grants Protalix Orphan Drug Designation for prGCD
08/25/09
Protalix Receives FDA Fast Track Designation for prGCD
08/17/09
U.S. Food and Drug Administration Approves Protalix's Treatment Protocol for prGCD
PROTALIX BIOTHERAPEUTICS
2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.
T: +972-4-9028100
F: +972-4-988-9489
E:
info@protalix.com
patient-info@protalix.com
© 2007 Protalix Biotherapeutics. All Rights Reserved.